Rebrands to Cipher Digital to Reflect Strategic Shift Toward HPC Divested 49% Stake in Alborz, Bear, and Chief Mining Sites Secured Full Funding for Existing Data Center Developments Through High-Yield Bond Offerings Data Center Development on Track at Barber Lake and Black Pearl NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced its fourth quarter and full year 2025 financial results, with an update on its operations and business strat ...

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody, in asthma. This announcement follows the recent initiation of the Company’s Phase 1b POC trial of ...

Highlights: CS25-063: 13 separate intervals, including: 75.4 m at 1.67% Li2O; and21.8 m at 1.12% Li2O.Mineralization encountered extend the boundary of the known Mineralized Zone to the west. CS25-064: Nine (9) separate intervals, including: 166.7 m at 1.47% Li2O. CS25-072: Eight (8) separate intervals, including: 82.1 m at 1.71% Li2O;109.5 m at 1.67% Li2O; and121.6 m at 1.45% Li2O. CS25-073: Five (5) separate intervals, including: 170.2 m at 1.99% Li2O, including 40.1 m at 2.89% Li2O;74.2 m at 0.94% Li2O;7 ...

– Record Quarterly Revenue of $148.3 million – – Quarterly Operating Profit of $17.4 million – – Quarterly Net Income of $8.1 million – – Quarterly Adjusted EBITDA1 of $30.3 million – – Record Backlog and Awarded Orders of $747.6 million – – Provides First Quarter and Full Year 2026 Outlook – PORTLAND, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) solutions and components, inclu ...

Revenues at the upper end of guidance and pivot to EBITDA profitability - expectations for 2026 unchanged and guidance reiterated Revenues expected to increase c.30% as OXB continues to execute its strategy, FY 2025 revenues expected to be £166-169 million (£168 - 171 million CC1), at the upper end of guidance of £160-170 million (CC) (FY 2024: £128.8 million)FY 2025 Operating EBITDA2 profitability expected to be mid-to-high single-digit £ million (CC) including a larger than expected non-recurring gain fro ...

2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Ad ...

RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to sche ...

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS) 24 February 2026 – Theon International Plc (THEON) (ISIN: CY0200751713) entered on 21st January 2026, into a Liquidity Contract with Kepler Cheuvreux (the "Liquidity Agreement"). Under the Liquidity Agreement, an initial amount of €1 million and 33,000 Shares were made available to Kepler Cheuvreux, to enhance the liquidity of the Shares in THEON on the regulated market of Euronext Amsterdam. On February 18, 2026, Parties have agreed that THEON will m ...

MONTRÉAL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX & NYSE) is pleased to announce that it has entered into a definitive agreement to acquire Terraco Gold Corp. (“Terraco”), a wholly-owned subsidiary of Sailfish Royalty Corp., which indirectly owns net smelter return (“NSR”) royalty assets (the “NSR Royalties”), largely consisting of royalties that cover Solidus Resources LLC’s (“Solidus”) Spring Valley Gold Project (“Spring Valley” or the “Project”) loca ...

Core Viewpoint - BioNTech SE will announce its financial results for Q4 and full year 2025 on March 10, 2026, and will host a conference call and webcast for stakeholders to discuss these results and provide a corporate update [1]. Company Overview - BioNTech is a global next-generation immunotherapy company focused on developing novel therapies for cancer and other serious diseases, utilizing a variety of computational discovery and therapeutic modalities [4]. - The company has a diversified portfolio of oncology product candidates, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies [4]. - BioNTech is also researching and developing multiple mRNA vaccine candidates for various infectious diseases, leveraging its expertise in mRNA development and in-house manufacturing capabilities [4]. - The company has established partnerships with several global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Pfizer, and Genentech, among others [4].